MA54318B1 - Formulations de capsules - Google Patents
Formulations de capsulesInfo
- Publication number
- MA54318B1 MA54318B1 MA54318A MA54318A MA54318B1 MA 54318 B1 MA54318 B1 MA 54318B1 MA 54318 A MA54318 A MA 54318A MA 54318 A MA54318 A MA 54318A MA 54318 B1 MA54318 B1 MA 54318B1
- Authority
- MA
- Morocco
- Prior art keywords
- compound
- solid solution
- methods
- capsule formulations
- capsules
- Prior art date
Links
- 239000007963 capsule composition Substances 0.000 title abstract 2
- 239000002775 capsule Substances 0.000 abstract 3
- 239000006104 solid solution Substances 0.000 abstract 3
- 229940125904 compound 1 Drugs 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 abstract 2
- 102000005590 Anaphylatoxin C5a Receptor Human genes 0.000 abstract 1
- 108010059426 Anaphylatoxin C5a Receptor Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Cardiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne des formulations de capsules en solution solide du composé 1 et leurs procédés de préparation. L'invention concerne également des méthodes de traitement d'individus souffrant d'une maladie ou d'un trouble impliquant l'activation pathologique de récepteurs c5a, ou prédisposés à celui-ci, par l'administration d'une quantité efficace d'une ou plusieurs capsules en solution solide comprenant le composé 1. L'invention concerne en outre des capsules posologiques unitaires comprenant certaines quantités du composé 1, et des kits comprenant une capsule en solution solide comprenant le composé 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862773848P | 2018-11-30 | 2018-11-30 | |
| PCT/US2019/063547 WO2020112961A1 (fr) | 2018-11-30 | 2019-11-27 | Formulations de capsules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA54318A MA54318A (fr) | 2021-10-06 |
| MA54318B1 true MA54318B1 (fr) | 2023-08-31 |
Family
ID=70849818
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA54318A MA54318B1 (fr) | 2018-11-30 | 2019-11-27 | Formulations de capsules |
| MA62992A MA62992B1 (fr) | 2018-11-30 | 2019-11-27 | Formulations de capsules |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA62992A MA62992B1 (fr) | 2018-11-30 | 2019-11-27 | Formulations de capsules |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US20200170957A1 (fr) |
| EP (3) | EP3886820B8 (fr) |
| JP (1) | JP7342124B2 (fr) |
| KR (1) | KR102586747B1 (fr) |
| CN (1) | CN113164403A (fr) |
| AR (1) | AR117219A1 (fr) |
| AU (1) | AU2019389031B2 (fr) |
| BR (1) | BR112021010285A2 (fr) |
| CA (1) | CA3120999C (fr) |
| CL (1) | CL2021001389A1 (fr) |
| CY (1) | CY1126079T1 (fr) |
| DK (2) | DK4233850T3 (fr) |
| ES (2) | ES2998858T3 (fr) |
| FI (2) | FI4233850T3 (fr) |
| HR (2) | HRP20241735T1 (fr) |
| HU (2) | HUE062551T2 (fr) |
| IL (1) | IL283450B2 (fr) |
| LT (2) | LT3886820T (fr) |
| MA (2) | MA54318B1 (fr) |
| MD (2) | MD3886820T2 (fr) |
| MX (1) | MX2021006242A (fr) |
| NZ (1) | NZ776554A (fr) |
| PL (2) | PL4233850T3 (fr) |
| PT (2) | PT4233850T (fr) |
| RS (2) | RS64250B1 (fr) |
| SG (1) | SG11202105572UA (fr) |
| SI (2) | SI3886820T1 (fr) |
| SM (2) | SMT202400521T1 (fr) |
| TW (1) | TWI827745B (fr) |
| WO (1) | WO2020112961A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7342124B2 (ja) | 2018-11-30 | 2023-09-11 | ケモセントリックス，インコーポレイティド | カプセル製剤 |
| CN114641288A (zh) | 2019-11-08 | 2022-06-17 | 凯莫森特里克斯股份有限公司 | 补体成分C5a受体的无定形形式 |
| CN116529241A (zh) * | 2020-10-28 | 2023-08-01 | 坎莫森特里克斯公司 | 治疗化脓性汗腺炎的方法 |
| MX2023004801A (es) | 2020-10-28 | 2023-05-10 | Chemocentryx Inc | Metodos de tratamiento de hidradenitis supurativa. |
| MX2023007420A (es) * | 2020-12-21 | 2023-06-29 | Chemocentryx Inc | Tratamiento de glomerulopatia c3 usando un inhibidor de c5a. |
| EP4514323A1 (fr) * | 2022-05-19 | 2025-03-05 | Dow Global Technologies LLC | Utilisation de complexes interpolymères à base de peg pour une solubilisation améliorée de médicaments de classe ii bcs |
| WO2025203055A1 (fr) * | 2024-03-26 | 2025-10-02 | Council Of Scientific And Industrial Research | Formulation de dihydrofolate encapsulée pour supplémentation alimentaire en tant que supplément nutraceutique efficace et son procédé de préparation |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR038681A1 (es) * | 2002-02-14 | 2005-01-26 | Solvay Pharm Bv | Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua |
| EP1817012A2 (fr) | 2004-11-24 | 2007-08-15 | Merck & Co., Inc. | Formulations pharmaceutiques liquides et semi-solides pour administration par voie orale d'un amide substitue |
| DE102005053066A1 (de) | 2005-11-04 | 2007-05-10 | Basf Ag | Verwendung von Copolymeren als Solubilisatoren für in Wasser schwerlöslichen Verbindungen |
| JP5819730B2 (ja) | 2008-12-22 | 2015-11-24 | ケモセントリックス，インコーポレイティド | Ｃ５ａＲアンタゴニスト |
| MX2012010478A (es) * | 2010-03-10 | 2013-02-01 | Abbott Lab | Composiciones solidas. |
| BR112012033075B1 (pt) * | 2010-06-24 | 2021-06-01 | Chemocentryx, Inc | Composto piperidina substituído antagonista de receptor c5a, composição farmacêutica, e, uso do composto |
| US9034858B2 (en) * | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| CA2823042C (fr) | 2010-12-27 | 2018-03-27 | Seven Generations Energy Ltd. | Procedes pour forage et stimulation de formations souterraines pour recuperer des ressources d'hydrocarbure et de gaz naturel |
| JP6666254B2 (ja) | 2014-02-05 | 2020-03-13 | レツク・フアーマシユーテイカルズ・デー・デー | アンドロゲン受容体アンタゴニストの固体医薬組成物 |
| NZ767823A (en) | 2014-09-29 | 2023-05-26 | Chemocentryx Inc | Processes and intermediates in the preparation of c5ar antagonists |
| KR102767008B1 (ko) | 2016-01-14 | 2025-02-11 | 케모센트릭스, 인크. | C3 사구체병증을 치료하는 방법 |
| MX384752B (es) | 2016-04-04 | 2025-03-14 | Chemocentryx Inc | ANTAGONISTAS SOLUBLES DE RECEPTOR DE C5a (C5aR). |
| TWI826364B (zh) | 2017-04-03 | 2023-12-21 | 德商因夫萊亞斯有限公司 | 活性抑制劑於發炎性疾病之治療 |
| US10376595B2 (en) * | 2017-04-03 | 2019-08-13 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5a activity |
| EP3703687A4 (fr) | 2017-10-30 | 2021-04-07 | ChemoCentryx, Inc. | Composés deutérés utilisés comme immunomodulateurs |
| WO2019089534A1 (fr) | 2017-10-31 | 2019-05-09 | Chemocentryx, Inc. | Réduction par inhibiteur de c5ar du taux urinaire de scd163 |
| MA52808A (fr) | 2018-06-07 | 2021-04-14 | Chemocentryx Inc | Dosage et effet d'un antagoniste de c5a avec une vasculite associée aux anca |
| JP7342124B2 (ja) | 2018-11-30 | 2023-09-11 | ケモセントリックス，インコーポレイティド | カプセル製剤 |
-
2019
- 2019-11-27 JP JP2021531035A patent/JP7342124B2/ja active Active
- 2019-11-27 WO PCT/US2019/063547 patent/WO2020112961A1/fr not_active Ceased
- 2019-11-27 MD MDE20210972T patent/MD3886820T2/ro unknown
- 2019-11-27 EP EP19889873.6A patent/EP3886820B8/fr active Active
- 2019-11-27 SI SI201930524T patent/SI3886820T1/sl unknown
- 2019-11-27 SM SM20240521T patent/SMT202400521T1/it unknown
- 2019-11-27 MA MA54318A patent/MA54318B1/fr unknown
- 2019-11-27 PT PT231602715T patent/PT4233850T/pt unknown
- 2019-11-27 EP EP23160271.5A patent/EP4233850B1/fr active Active
- 2019-11-27 FI FIEP23160271.5T patent/FI4233850T3/fi active
- 2019-11-27 IL IL283450A patent/IL283450B2/en unknown
- 2019-11-27 SG SG11202105572UA patent/SG11202105572UA/en unknown
- 2019-11-27 EP EP24196793.4A patent/EP4487915A3/fr active Pending
- 2019-11-27 FI FIEP19889873.6T patent/FI3886820T3/fi active
- 2019-11-27 MX MX2021006242A patent/MX2021006242A/es unknown
- 2019-11-27 HU HUE19889873A patent/HUE062551T2/hu unknown
- 2019-11-27 LT LTEPPCT/US2019/063547T patent/LT3886820T/lt unknown
- 2019-11-27 LT LTEP23160271.5T patent/LT4233850T/lt unknown
- 2019-11-27 MD MDE20231131T patent/MD4233850T2/ro unknown
- 2019-11-27 DK DK23160271.5T patent/DK4233850T3/da active
- 2019-11-27 PL PL23160271.5T patent/PL4233850T3/pl unknown
- 2019-11-27 ES ES23160271T patent/ES2998858T3/es active Active
- 2019-11-27 US US16/697,523 patent/US20200170957A1/en not_active Abandoned
- 2019-11-27 NZ NZ776554A patent/NZ776554A/en unknown
- 2019-11-27 DK DK19889873.6T patent/DK3886820T3/da active
- 2019-11-27 BR BR112021010285-0A patent/BR112021010285A2/pt not_active Application Discontinuation
- 2019-11-27 CA CA3120999A patent/CA3120999C/fr active Active
- 2019-11-27 MA MA62992A patent/MA62992B1/fr unknown
- 2019-11-27 RS RS20230433A patent/RS64250B1/sr unknown
- 2019-11-27 HR HRP20241735TT patent/HRP20241735T1/hr unknown
- 2019-11-27 RS RS20241401A patent/RS66362B1/sr unknown
- 2019-11-27 KR KR1020217019883A patent/KR102586747B1/ko active Active
- 2019-11-27 PT PT198898736T patent/PT3886820T/pt unknown
- 2019-11-27 SI SI201930868T patent/SI4233850T1/sl unknown
- 2019-11-27 AU AU2019389031A patent/AU2019389031B2/en active Active
- 2019-11-27 SM SM20230153T patent/SMT202300153T1/it unknown
- 2019-11-27 CN CN201980079276.4A patent/CN113164403A/zh active Pending
- 2019-11-27 ES ES19889873T patent/ES2943492T3/es active Active
- 2019-11-27 HR HRP20230551TT patent/HRP20230551T1/hr unknown
- 2019-11-27 HU HUE23160271A patent/HUE069633T2/hu unknown
- 2019-11-27 PL PL19889873.6T patent/PL3886820T3/pl unknown
- 2019-11-29 TW TW108143799A patent/TWI827745B/zh active
- 2019-11-29 AR ARP190103505A patent/AR117219A1/es unknown
-
2021
- 2021-05-27 CL CL2021001389A patent/CL2021001389A1/es unknown
- 2021-12-08 US US17/545,878 patent/US11951214B2/en active Active
-
2023
- 2023-07-03 CY CY20231100309T patent/CY1126079T1/el unknown
-
2024
- 2024-02-09 US US18/437,368 patent/US20240299306A1/en not_active Abandoned
-
2025
- 2025-08-28 US US19/313,405 patent/US20250375385A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54318B1 (fr) | Formulations de capsules | |
| MA51530B1 (fr) | Composés cycliques fondus | |
| MA43817B1 (fr) | Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2 | |
| MA57412B1 (fr) | Benzopyrrole substitués et inhibiteurs du complément structurellement apparentés | |
| MA43979B1 (fr) | Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu'inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques | |
| MA37958B1 (fr) | Pde9i ayant un squelette imidazo pyrazinone | |
| MA51204B1 (fr) | Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique | |
| MA33552B1 (fr) | Énantiomères de composés de spiro-oxindole et leurs utilisations en tant qu'agents thérapeutiques | |
| MA40111B1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| MA30607B1 (fr) | N-phenylmethyl -5-oxo-proline-2-amides substitues tenant lieu d'antagonistes du recepteur p2x7 et procedes d'utilisation | |
| MA55402B1 (fr) | Dérivés de 7-benzyl-4-(2-méthylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, leurs sels et leur utilisation en thérapie | |
| TN2009000428A1 (fr) | Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale | |
| MA33923B1 (fr) | Dérivés hétéroaromatiques de phénylimidazole en tant qu'inhibiteurs de l'enzyme pde10a | |
| MA44037B1 (fr) | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci | |
| MA46342B1 (fr) | Dérivés de chromane, d'isochromane et de dihydroisobenzofurane en tant que modulateurs allostériques négatifs de mglur2, compositions et leur utilisation | |
| MA42301B1 (fr) | Sel cristallin de fumarate de (s)-[3,4-difluoro-2-(2-fluoro-4-iodophénylamino)phényl][3-hydroxy-3-(pipéridin-2-yl)azétidin-1-yl]-méthanone | |
| MA35875B1 (fr) | Dérivés d'aza-adamantane et leurs utilisations | |
| MA39253B1 (fr) | Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr | |
| MA60154A1 (fr) | Inhibiteurs de line-1 pour traiter une maladie | |
| MA45202B1 (fr) | Composition pharmaceutique comprenant un antagoniste du récepteur minéralocorticoïde et son utilisation | |
| MA54940B1 (fr) | Dérivés d'acides aminés pour le traitement de maladies inflammatoires | |
| MA53521B1 (fr) | Nouveaux composés inhibiteurs de la protéase mpro et de la réplication du sars-cov2, leurs formulations et applications | |
| MA34327B1 (fr) | Dérivés de flufénoxine pour le traitement et la prévention des pathologies amyloïdes | |
| FR3092580B1 (fr) | Nouveaux dérivés azobenzènes, leur procédé de préparation et leur utilisation pour le traitement thérapeutique associé à des radiations ionisantes | |
| MA35882B1 (fr) | Inhibiteurs de pde9 comprenant un squelette imidazotriazinone |